References
- CalzaLManfrediRPocaterraD2008Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based anti-retroviral treatment in 82 therapy-nayive patients with HIV-1 infectionInt J STD AIDS19541418663041
- ClumeckNPozniakARaffiF2008European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adultsHIV Med9657118257769
- CooperCLVan HeeswijkRPGallicanoK2003A review of low-dose ritonavir in protease inhibitor combination therapyClin Infect Dis3615859212802760
- DeJesusELaMarcaASensionM2003The Context Study: Efficacy and safety of GW433908/RTV in PI-experienced Subjects with viroogical failure (24 weeks results)10th Conference on Retroviruses and Opportunistic InfectionsBoston, MA, USA
- EronJJrYeniPGatheJJr2006The KLEAN study of fosamprenavirritonavir versus lopinavirritonavir, each in combination with abacavirlamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialLancet3684768216890834
- FurfineESBakerCTHaleMR2004Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavirAntimicrob Agents Chemother48791814982766
- GatheJCJrIvePWoodR2004SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelf inavir in naive HIV-1-infected patientsAids1815293715238771
- GatheJDSLoutfyBPodzamczerM2008Study M05–730 primary efficacy results at week 48: Phase 3, randomized, open-label study of lopinavir/ritonavir tablets once daily vs twice daily, co-administered with tenofovir df+emtricitabine in ARV-naïve HIV-1-infected subjects15th Conference on Retroviruses and Opportunistic InfectionsBoston, MA, USA
- HicksCDWohlELiaoD2007Once-daily fosamprenavir (FPV) boosted with either 100 mg or 200 mg of ritonavir (r) and combined with abacavir (ABC)/lamivudine (3TC): 48-week safety and efficacy results from COL10075811th European AIDS ConferenceMadrid, Spain
- OrtizRDejesusEKhanlouH2008Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48Aids2213899718614861
- Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescentsDepartment of Health and Human Services12920081128 URL: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
- Rodriguez-FrenchABoghossianJGrayGE2004The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patientsJ Acquir Immune Defic Syndr35223214707788
- RuanePJLuberADWireMB2007Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteersAntimicrob Agents Chemother51560517088488
- SadlerBMHansonCDChittickGE1999Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adultsAntimicrob Agents Chemother4316869210390223
- SadlerBMPilieroPJPrestonSL2001Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteersAids1510091811399983
- SmithKYWeinbergWGDejesusE2008Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERTAIDS Res Ther5518373851
- WalmsleySRSlimKWardJ2007Saquinavir/r (SQV/r) BiD versus lopinavir/r (LPV/r) BiD, plus emtricitabine/tenofovir (FTC/TDF) QD as initial therapy in HIV-1 infected patients: the GEMINI study11th European AIDS ConferenceMadrid, Spain
- WoodRArastehKStellbrinkHJ2004Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patientsAntimicrob Agents Chemother481162314693528